IL6 and COVID-19: As mentioned above, neutering IL-6 was shown to reduce cardiac fibroblast activation in mice, so we propose that tocilizumab may also have a bearing on combating myocardial fibrosis caused by COVID-19, but clinical epidemiological evidence is not currently available.